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Background: Bronchial asthma is known as a risk factor of admission to the intensive care unit. 
However, the mechanism by which pandemic 2009 H1N1 (A(H1N1)pdm09) infection 
increases the severity of symptoms in patients with bronchial asthma is unknown; therefore, 
we aimed at determining this mechanism. 
Methods: Inflammatory cell levels in the bronchoalveolar lavage (BAL) fluid from the 
non-asthma/mock, non-asthma/A(H1N1)pdm09, asthma/mock, and asthma/A(H1N1)pdm09 
groups were determined using BALB/c mice. Cell infiltration levels, cytokine levels, and viral 
titers were compared among the groups. 
Results: Neutrophil, monocyte, interleukin (IL)-5, IL-6, IL-10, IL-13, and tumor necrosis 
factor (TNF)- levels were significantly higher in the BAL fluid from the 
non-asthma/A(H1N1)pdm09 and asthma/A(H1N1)pdm09 groups than in the mock groups (p
< 0.05 for neutrophils and monocytes; p < 0.01 for the rest). The number of eosinophils and 
CD8+ lymphocytes and the level of transforming growth factor beta 1 (TGF-1) in BAL fluid 
in the asthma/A(H1N1)pdm09 group were significantly higher among all groups (p < 0.05 for 
eosinophils and CD8+ lymphocytes; p < 0.01 for TGF-1). The levels of IL-6, IL-10, IL-13, 
and TNF- were significantly higher in the asthma/A(H1N1)pdm09 group than in the 
non-asthma/A(H1N1)pdm09 group (p < 0.05 for IL-6 and IL-10; p < 0.01 for IL-13 and 
TNF-). The level of IFN- in the asthma/A(H1N1)pdm09 group was significantly lower than 
that in the non-asthma/A(H1N1)pdm09 group (p < 0.05). The viral titers in the BAL fluids 
were higher in the asthma/A(H1N1)pdm09 group than in the non-asthma/A(H1N1)pdm09 
group (p < 0.05). Histopathological examination showed more severe infiltration of 
inflammatory cells and destruction of lung tissue in the asthma/A(H1N1)pdm09 group than in 
the non-asthma/A(H1N1)pdm09 group.
Conclusions: Severe pulmonary inflammation induced by elevated levels of cytokines, 
combined with increased viral replication due to decreased IFN- levels, may contribute to 
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worsening respiratory symptoms in patients with bronchial asthma and A(H1N1)pdm09 
infection. 
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1. Introduction 
The 2009 pandemic H1N1 (A(H1N1)pdm09) influenza virus originated in pigs and 
emerged among humans in Mexico during the spring of 2009 before spreading globally [1]. 
Most cases of A(H1N1)pdm09 infection involved mild symptoms, but some patients had 
severe respiratory problems such as severe pneumonia and acute respiratory distress syndrome 
(ARDS); these were particularly common in children and young adults [1-4]. In children, 
bronchial asthma increases the risk of admission to the hospital and intensive care unit [4-7]. A 
cytokine-mediated inflammatory response has been well documented in cases of pneumonia 
and ARDS [8-10], but to our knowledge, there are no published findings regarding the 
cytokine profile of bronchoalveolar lavage (BAL) fluid from patients who have bronchial 
asthma and are also infected by A(H1N1)pdm09. Thus, the mechanism by which 
A(H1N1)pdm09 infection increases the severity of symptoms in patients with bronchial asthma 
remains unclear. 
In this study, we investigated the levels of cytokines and viral titers in BAL fluid in a 
mouse model of bronchial asthma with A(H1N1)pdm09 infection to determine the mechanism 
by which A(H1N1)pdm09 infection increases the severity of symptoms in mice with bronchial 
asthma. 
2. Material and methods 
2.1. Sensitization and allergen challenge of mice 
BALB/c mice aged 68 weeks (Chiyoda Kaihatsu Co. Ltd. Tokyo, Japan) were 
sensitized and challenged with grade II ovalbumin (OVA; Sigma Chemical Co., St. Louis, MO, 
USA) or phosphate-buffered saline (PBS). For sensitization, mice were injected 
subcutaneously on days 0 and 14 with 50 g OVA, which was dissolved in 300 l PBS 
containing 2 mg aluminum hydroxide (alum; Wako Pure Chemical Industries, Ltd., Osaka, 
Japan). On days 22, 24, 26, and 28, the mice inhaled 1% (w/v) OVA in PBS for 30 min via a 
nebulizer (Fig. 1). We used PBS as a control in all procedures. Successful induction of the 
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mouse asthma model was assessed by determining the total number of cells and eosinophils in 
the BAL fluid. A total of 6 experiments using 58 mice in each group were performed. All the 
experimental protocols related to the mice were reviewed by the Committee for Ethics on 
Animal Experiments of Yamaguchi University Graduate School of Medicine. 
2.2. Viruses and infection of mice 
The mouse adapted A(H1N1)pdm09 virus (strain: A/Narita/1/09) was provided by the 
National Institute of Infectious Diseases (Tokyo, Japan). A/Narita/1/2009 was isolated from a 
patient, and propagated in Madin-Darby canine kidney (MDCK) cells. The isolate obtained 
was serially passaged 15 times in BALB/c mice. After intranasal inoculation of 20 µL of viral 
suspension, 3 mice were sacrificed on day 3 after inoculation and their bronchoalveolar wash 
fluids were collected. These bronchoalveolar fluids were pooled and then used to inoculate 3 
additional BALB/c mice, whose bronchoalveolar fluids on day 3 after inoculation were used to 
inoculate fresh mice. 
On day 31, influenza virus was administered intranasally at a concentration of 1 × 106
pfu/20 l (non-asthma/A(H1N1)pdm09 and asthma/A(H1N1)pdm09 groups); uninfected 
groups were administered 20 l PBS (non-asthma/mock and asthma/mock groups). The mice 
were euthanized, and samples were collected on day 38 (post-infection day 7). A total of 6 
experiments using 58 mice in each group were performed. 
2.3. Preparation of BAL fluid 
BAL fluid was collected on day 38 (post-infection day 7) by using 3 consecutive 
instillations of PBS (1 ml) at room temperature and was centrifuged at 1,500 rpm at 4°C for 5 
min; supernatants were collected and stored at 80°C for measurement of cytokine levels. Cell 
pellets were resuspended in 500 l PBS and used for analysis of cellular infiltration. Cytospin 
samples were prepared using Auto Smear CF-12D (Sakura Co., Tokyo, Japan), and cellular 
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infiltration in BAL fluid was assessed on Wright-Giemsastained slides (Wako Pure Chemical 
Industries, Ltd).
2.4. Measurement of CD4+ and CD8+ lymphocytes in BAL fluid 
Cell pellets were resuspended in PBS and stained with fluorescein isothiocyanate 
(FITC)-conjugated anti-CD4 (BD Biosciences, San Jose, CA., USA) and allophycocyanin 
(APC)-conjugated anti-CD8 (BD Biosciences) antibodies; erythrocytes were lysed by the 
addition of FACS Lysing Solution (Becton Dickinson, San Diego, CA, USA). The cell 
suspensions were centrifuged, and the cell pellets were resuspended in PBS containing sodium 
azide and paraformaldehyde. The cells were analyzed using a FACSCalibur flow cytometer 
(Becton Dickinson) equipped with the CellQuest software (Becton Dickinson). At least 10,000 
cells were analyzed for each mouse in the flow cytometric studies. 
2.5. Cytokine assays 
The concentrations of cytokines in BAL fluid were measured. The levels of 
interleukin (IL)-2, IL-4, IL-6, IL-10, IL-17A, interferon (IFN)-, and tumor necrosis factor 
(TNF)- were measured using a cytometric bead array (CBA) kit (BD Biosciences). The levels 
of IL-5, IL-12, IL-13, and transforming growth factor beta 1 (TGF-1) were measured using an 
enzyme-linked immunosorbent assay (ELISA; R&D Systems, Minneapolis, MN, USA). The 
CBA assay and ELISA were performed in accordance with the manufacturers instructions. 
The lower detection limits for IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17A, IFN-, 
TNF-, and TGF-1 were 0.1, 0.03, 7, 1.4, 16.8, 2.5, 1.5, 0.8, 0.5, 0.9, and 4.6 pg/ml 
respectively. A total of 5 experiments using 58 mice in each group were performed for the 
cytokine assays. 
2.6. Plaque assay 
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MDCK cells were maintained at 37°C in humidified 5% CO2 in a stationary culture. 
Six-well plates were seeded with 1 × 106 cells in each well and cultured in -minimum 
essential medium (MEM; GIBCO/Invitrogen, Carlsbad, CA, USA) containing 10% fetal 
bovine serum (FBS), 100 units/ml penicillin (GIBCO), and 100 g/ml streptomycin (GIBCO). 
After the cells were washed twice in serum-free Dulbeccos modified Eagles medium 
(DMEM; GIBCO/Invitrogen), they were maintained in serum-free DMEM at 37°C for 1 h 
before being overlaid with 200 l/well of suitably diluted BAL and incubated at 37°C for 1 h. 
After the cells were washed once in serum-free DMEM, they were overlaid with serum-free 
DMEM containing 0.8% agarose (Becton Dickinson, Franklin Lakes, NJ, USA), 0.1% 
diethylaminoethyl-dextran (Sigma-Aldrich, Co., St Louis, MO, USA), and 7 g/ml trypsin 
(Sigma-Aldrich, Co.). The cells were further cultured for 72 h at 37°C, fixed in 10% 
formaldehyde (Wako Pure Chemical Industries, Ltd), and stained with 0.037% methylene blue 
(Wako Pure Chemical Industries, Ltd). Each experiment was performed in duplicate wells. 
2.7. Histopathological examination of the lungs 
Lung tissues were fixed in 10% formalin for 24 h at room temperature and embedded 
in paraffin. Three-micrometer-thick serial sections were cut and stained with hematoxylin and 
eosin (HE) (Muto Pure Chemicals Co. Ltd., Tokyo, Japan). The sections were observed using 
light microscopy to evaluate the degree of airway inflammation.
2.8. Statistical analysis 
The results were analyzed using the Mann-Whitney U-test; p-values of <0.05 were 
considered significant. Analyses and calculations were performed using ystat2008.xls 
(Igakutosho-shuppan Ltd, Tokyo, Japan). 
3. Results 
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3.1. Analysis of the cells in the BAL fluid 
The number of inflammatory cells in the BAL fluid from the different groups is 
illustrated in Fig. 2. The number of neutrophils and monocytes in the 
non-asthma/A(H1N1)pdm09 and asthma/A(H1N1)pdm09 groups was significantly higher 
than that in the mock groups (all p < 0.05). The number of eosinophils in the asthma/mock 
group was significantly higher than that in the non-asthma/mock and 
non-asthma/A(H1N1)pdm09 groups (both p < 0.05), and the number of eosinophils in the 
asthma/A(H1N1)pdm09 groups was significantly higher than that in the 3 other groups (all p
< 0.05). Furthermore, the number of lymphocytes in the asthma/mock, 
non-asthma/A(H1N1)pdm09, and asthma/A(H1N1)pdm09 groups was significantly higher 
than that in the non-asthma/mock group (all p < 0.05), and the number of lymphocytes in the 
asthma/A(H1N1)pdm09 group was significantly higher than that in the 
non-asthma/A(H1N1)pdm09 group (p < 0.05). Fig. 3 shows the number of CD4+ and CD8+
lymphocytes in the BAL fluid. The number of CD4+ lymphocytes in the asthma/mock and 
asthma/A(H1N1)pdm09 groups was significantly higher than that in the non-asthma/mock 
group (all p < 0.05). The number of CD8+ lymphocytes in the non-asthma/A(H1N1)pdm09 
group was significantly higher than that in the non-asthma/mock and asthma/mock groups 
(both p < 0.05). Finally, the number of CD8+ lymphocytes in the asthma/A(H1N1)pdm09 
group was significantly higher than that in the 3 other groups (all p < 0.05). 
3.2. Cytokine concentrations in BAL fluid 
The cytokine levels in BAL fluid are shown in Fig. 4. The levels of IL-5 (data not 
shown), IL-6, IL-10, IL-13, IFN-, and TNF- in the non-asthma/A(H1N1)pdm09 and 
asthma/A(H1N1)pdm09 groups were significantly higher than those in the non-asthma/mock 
and asthma/mock groups (all p < 0.01). The levels of TGF-1 in the asthma/mock, 
non-asthma/A(H1N1)pdm09, and asthma/A(H1N1)pdm09 groups were significantly higher 
than those in the non-asthma/mock group (all p < 0.01). The levels of IL-6, IL-10, IL-13, 
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TNF-, and TGF-1 in the asthma/A(H1N1)pdm09 group were significantly higher than those 
in the non-asthma/A(H1N1)pdm09 group (p < 0.05, p < 0.05, p < 0.01, p < 0.01, and p < 0.01, 
respectively). In contrast, the levels of IFN- in the asthma/A(H1N1)pdm09 group were 
significantly lower than those in the non-asthma/A(H1N1)pdm09 group (p < 0.05). There 
were no significant differences among the 4 groups with respect to the levels of IL-2, IL-4, 
IL-12 or IL-17A (data not shown). 
3.3. Viral titers in BAL fluid 
Fig. 5 shows the viral titers in BAL fluid on post-infection day 7. The viral titers in 
the asthma/A(H1N1)pdm09 group (mean ± SEM; 2.2 ± 5.1 × 105 pfu/mL) were significantly 
higher than those in the non-asthma/A(H1N1)pdm09 group (mean ± SEM; 2.6 ± 3.8 × 104
pfu/mL) (p < 0.05). 
3.4. Histopathological findings for the lungs 
Fig. 6 shows the lung tissues of mice stained with HE. The asthma/mock group had 
greater thickening of the basement membrane of bronchi and infiltration of inflammatory cells 
around vessels than the non-asthma/mock controls. Infiltration of inflammatory cells and 
tissue destruction in the non-asthma/A(H1N1)pdm09 and asthma/A(H1N1)pdm09 groups 
were greater than those in mock groups. Furthermore, the degree of inflammatory cell 
infiltration and tissue destruction were more severe in the asthma/A(H1N1)pdm09 group than 
in the non-asthma/A(H1N1)pdm09 group. 
4. Discussion 
To our knowledge, this is the first report of BAL fluid analysis in 
A(H1N1)pdm09-infected mice with bronchial asthma. The results show that A(H1N1)pdm09 
infection induces high levels of pro-inflammatory cytokines such as IL-6 and TNF- in BAL 
fluid and that this increase is enhanced by the presence of bronchial asthma.
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IL-6 and TNF- are known as pro-inflammatory cytokines [11-13]. The levels of 
these cytokines are elevated in the sputum and BAL fluid of patients with asthma and are 
thought to play a critical role in the initiation, maintenance, and progression of airway 
inflammation in asthma [13-15]. Administration of TNF- leads to an increase in both airway 
hyper-responsiveness and the infiltration of neutrophils in the airway [16,17]; this is explained 
by the direct effect of TNF- and the indirect effect of cysteinyl leukotriene release [18,19]. 
TNF- is also known to contribute to acute lung injury (ALI) and ARDS [20-22]. The 
A(H1N1)pdm09 virus can infect both type I and II alveolar epithelial cells [23]; 
A(H1N1)pdm09 infection of type II alveolar epithelial cells may decrease the synthesis of 
pulmonary surfactant and lead to plastic bronchitis. In addition, the elevation in TNF- during 
A(H1N1)pdm09 infection may exacerbate lung damage and bronchial asthma. The 
histopathological findings obtained for the lungs during this study are consistent with our 
hypothesis. The levels of IL-10 in the asthma/A(H1N1)pdm09 group were also significantly 
higher than those in the non-asthma/A(H1N1)pdm09 group, indicating significant elevation of 
IL-6 and TNF- levels, as IL-10 inhibits the production of pro-inflammatory cytokines such 
as TNF-, IL-1, IL-6, and IL-12 [24-29]. TGF-1 plays a key role in inflammation in asthma 
and has anti-inflammatory properties since it can regulate lymphocyte homeostasis by 
inhibiting Th-1 and Th-2 cell responses and promoting the differentiation of Treg cells [30]. 
In this study, the elevated levels observed for TGF-1 may indicate anti-inflammatory actions. 
On the other hand, TGF-1 also has pro-inflammatory properties [30]. Thus, it may have 
contributed to the exacerbation of bronchial asthma via its pro-inflammatory role in our 
model. 
IL-13 is a Th-2 cytokine produced by T cells, natural killer cells, mast cells. It plays a 
pivotal role in the onset or exacerbation of human bronchial asthma [31]. In a previous report, 
the serum levels of IL-13 were found to be elevated in children with A(H1N1)pdm09 
infection [32]. Our results indicated that an increased level of IL-13 in BAL fluid appears to 
contribute to worsening of respiratory symptoms in patients who have bronchial asthma and 
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are infected by A(H1N1)pdm09. IL-5 is also a Th-2 cytokine that plays an important role in 
the exacerbation of human bronchial asthma symptoms [33]. In this experimental system, the 
levels of IL-5 in the non-asthma/A(H1N1)pdm09 and asthma/A(H1N1)pdm09 groups were 
indeed significantly higher than those in the mock groups, although we do not believe that this 
difference is closely related to exacerbation, since the differences between the groups were 
slight. In contrast, the levels of IFN- in the asthma/A(H1N1)pdm09 group were significantly 
lower than those in the non-asthma/A(H1N1)pdm09 group. IFN- is produced by T cells, 
monocytes, macrophages, dendritic cells, and natural killer T cells, and its secretion is 
indicative of a Th-1-mediated inflammatory response [34]. The production of IFN- reduced 
in patients with bronchial asthma, indicating an alteration in the cytokine milieu, with an 
excess of Th-2 products and a decrease in Th-1 products [34,35]. In this regard, our data are 
consistent with those of previous reports. IFN- activates macrophages, which enhances its 
ability to kill intracellular pathogens [36]. Cytotoxic CD8+ T cells also produce IFN-, and 
this may represent an accessory mechanism by which they eliminate viruses from infected 
tissues [36]. In this study, the number of CD8+ T cells in the asthma/A(H1N1)pdm09 group 
was significantly higher but the levels of IFN- were significantly lower than those in the 
non-asthma/A(H1N1)pdm09 group. This discrepancy can be explained by focusing on natural 
killer (NK) cell activity. Kawakami et al. examined NK cell activity in a mouse model of 
eczema vaccinatum [37] and found that the number of NK and CD8+ T cells in the affected 
lesions was significantly higher in mice with eczema vaccinatum, while NK cell activity, 
including IFN- production, was significantly lower in these mice than in the control group 
[37]. The decrease in the activity of NK cells in bronchial asthma patients may be attributable 
to the fact that bronchial asthma is an atopic disease like atopic dermatitis. The viral titers in 
BAL fluid in the asthma/A(H1N1)pdm09 group were significantly higher than those in the 
non-asthma/A(H1N1)pdm09 group in our study. We believe that decreasing innate 
immunity-related activity, including NK cell activity and IFN- synthesis in the lungs, may 
contribute to the high replication rate of A(H1N1)pdm09. 
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Our present study has several limitations. The data shown in this report were only 
obtained at day 7 post-infection. Additionally, we did not investigate NK cell activity because 
NK activation does not occur in this model at day 7 post-infection, and we would need to 
obtain the results at different timepoints. Thus, further studies are required in order to clarify 
the relationship between A(H1N1)pdm09 infection and asthma. 
In conclusion, our results demonstrate that A(H1N1)pdm09 infection induces severe 
pulmonary inflammation in a mouse model of asthma. This mechanism, combined with 
increased viral replication due to decreased IFN- levels, may increase the severity of 
symptoms in humans who have bronchial asthma and are also exposed to A(H1N1)pdm09. 
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Figure legends 
Figure 1. Study design. Ovalbumin (OVA)-sensitized mice were immunized with OVA plus 
alum subcutaneously (s.c.) on days 0 and 14. On days 22, 24, 26, and 28, the mice inhaled 1% 
(w/v) OVA/PBS or PBS for 30 min via a nebulizer. On day 31, the mice were infected with 
the pandemic H1N1 2009 (A(H1N1)pdm09) influenza virus. The mice were euthanized on 
day 38, and bronchoalveolar lavage (BAL) fluid was collected. Abbreviations: i.h., inhale; 
p.i.d., post-infection day 
Figure 2. Differential cell counts in bronchoalveolar lavage (BAL) fluids collected from mice. 
The data shown represent the mean ± SEM values. * p < 0.05 vs. non-asthma/mock. # p < 
0.05 vs. asthma/mock. $ p < 0.05 vs. non-asthma/A(H1N1)pdm09 (n = 5 per group). 
Figure 3. Number of CD4+ T cells and CD8+ T cells in bronchoalveolar lavage (BAL) fluid 
collected from mice. The data shown represent the mean ± SEM values. * p < 0.05 vs. 
non-asthma/mock. # p < 0.05 vs. asthma/mock. $ p < 0.05 vs. non-asthma/A(H1N1)pdm09 (n 
= 5 per group). 
Figure 4. Concentrations of interleukin (IL)-5, IL-6, IL-10, IL-13, interferon (IFN)-, tumor 
necrosis factor (TNF)-, and transforming growth factor beta 1 (TGF-1) in bronchoalveolar 
lavage (BAL) fluid from mice. The data shown represent the mean ± SEM values. The results 
shown are representative of 5 experiments using 58 mice in each group. ** p < 0.01 vs. 
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non-asthma/mock. ## p < 0.01 vs. asthma/mock. $ p < 0.05 vs. non-asthma/A(H1N1)pdm09. 
$$ p < 0.01 vs. non-asthma/A(H1N1)pdm09. 
Figure 5. A plaque assay was performed to detect viral titers in the bronchoalveolar lavage 
(BAL) fluid. The data shown represent the mean ± SEM values. The results shown are 
representative of 5 experiments using 58 mice in each group. * p < 0.05. 
Figure 6. Photomicrographs of HE-stained lung tissue from each group: (a) non-asthma/mock 
group (×40), (b) asthma/mock group (×40), (c) non-asthma/A(H1N1)pdm09 group (×40), (d) 
asthma/A(H1N1)pdm09 group (×40), (e) non-asthma/mock group (×100), (f) asthma/mock 
group (×100), (g) non-asthma/A(H1N1)pdm09 group (×100), and (h) asthma/A(H1N1)pdm09 
group (×100). Similar results were obtained in 3 independent mice from each group. 
Representative findings are shown.
